Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.61 |
| ▸ | DCTPP1 | Q9H773 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452386 | 0.88 | ALDH1A1 (0.51) | PDE10ADCTPP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5452368 | 0.86 | ADORA2A (0.51) | PDE10ADCTPP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17283025 | 0.86 | ALDH1A1 (0.49) | PDE10ADCTPP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6078154 | 0.85 | ALDH1A1 (0.48) | PDE10ADCTPP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22438726 | 0.82 | DCTPP1 (0.54) | PDE10ADCTPP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL27837031 | 0.81 | PI4KA (0.48) | PDE10AALDH1A1LMNASMN1; SMN2ALOX15 | |
| SCHEMBL21174200 | 0.80 | TLR7 (0.57) | PDE10AALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL5466105 | 0.78 | PDE10A (0.55) | PDE10ADCTPP1ALDH1A1KDM4EMAPT | |
| SCHEMBL5465357 | 0.76 | HPGD (0.64) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15719155 | 0.75 | ADORA2A (0.45) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | PDE10A 1512/4885DCTPP1 77/4885ALDH1A1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.